1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Simcere Pharmaceutical Group - Product Pipeline Review - 2016

Simcere Pharmaceutical Group - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 53 pages

Simcere Pharmaceutical Group - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Simcere Pharmaceutical Group - Product Pipeline Review - 2016’, provides an overview of the Simcere Pharmaceutical Group’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Simcere Pharmaceutical Group, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Simcere Pharmaceutical Group
- The report provides overview of Simcere Pharmaceutical Group including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Simcere Pharmaceutical Group’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Simcere Pharmaceutical Group’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Simcere Pharmaceutical Group’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Simcere Pharmaceutical Group
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Simcere Pharmaceutical Group’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Simcere Pharmaceutical Group - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Simcere Pharmaceutical Group Snapshot 6
Simcere Pharmaceutical Group Overview 6
Key Information 6
Key Facts 6
Simcere Pharmaceutical Group - Research and Development Overview 7
Key Therapeutic Areas 7
Simcere Pharmaceutical Group - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Simcere Pharmaceutical Group - Pipeline Products Glance 15
Simcere Pharmaceutical Group - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Simcere Pharmaceutical Group - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Simcere Pharmaceutical Group - Early Stage Pipeline Products 18
IND/CTA Filed Products/Combination Treatment Modalities 18
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Simcere Pharmaceutical Group - Drug Profiles 21
SIM-071201 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
bendamustine hydrochloride 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
(amlodipine besylate + irbesartan) 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
APX-003 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
metatinib tromethamine 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
abatacept 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
BMS-817378 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
OSI-930 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
SIM-010603 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
SIM-0710 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
BMS-795311 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
SCR-1693 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
SIM-89 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Small Molecule for Cancer 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Simcere Pharmaceutical Group - Pipeline Analysis 38
Simcere Pharmaceutical Group - Pipeline Products by Target 38
Simcere Pharmaceutical Group - Pipeline Products by Route of Administration 40
Simcere Pharmaceutical Group - Pipeline Products by Molecule Type 41
Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action 42
Simcere Pharmaceutical Group - Recent Pipeline Updates 44
Simcere Pharmaceutical Group - Dormant Projects 49
Simcere Pharmaceutical Group - Locations And Subsidiaries 50
Head Office 50
Other Locations and Subsidiaries 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables
Simcere Pharmaceutical Group, Key Information 6
Simcere Pharmaceutical Group, Key Facts 6
Simcere Pharmaceutical Group - Pipeline by Indication, 2016 8
Simcere Pharmaceutical Group - Pipeline by Stage of Development, 2016 10
Simcere Pharmaceutical Group - Monotherapy Products in Pipeline, 2016 11
Simcere Pharmaceutical Group - Combination Treatment Modalities in Pipeline, 2016 12
Simcere Pharmaceutical Group - Partnered Products in Pipeline, 2016 13
Simcere Pharmaceutical Group - Partnered Products/ Combination Treatment Modalities, 2016 14
Simcere Pharmaceutical Group - Phase III, 2016 15
Simcere Pharmaceutical Group - Phase II, 2016 16
Simcere Pharmaceutical Group - Phase I, 2016 17
Simcere Pharmaceutical Group - IND/CTA Filed, 2016 18
Simcere Pharmaceutical Group - Preclinical, 2016 19
Simcere Pharmaceutical Group - Discovery, 2016 20
Simcere Pharmaceutical Group - Pipeline by Target, 2016 38
Simcere Pharmaceutical Group - Pipeline by Route of Administration, 2016 40
Simcere Pharmaceutical Group - Pipeline by Molecule Type, 2016 41
Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action, 2016 43
Simcere Pharmaceutical Group - Recent Pipeline Updates, 2016 44
Simcere Pharmaceutical Group - Dormant Developmental Projects,2016 49
Simcere Pharmaceutical Group, Subsidiaries 50

List of Figures
Simcere Pharmaceutical Group - Pipeline by Top 10 Indication, 2016 8
Simcere Pharmaceutical Group - Pipeline by Stage of Development, 2016 10
Simcere Pharmaceutical Group - Monotherapy Products in Pipeline, 2016 11
Simcere Pharmaceutical Group - Partnered Products in Pipeline, 2016 13
Simcere Pharmaceutical Group - Pipeline by Top 10 Target, 2016 38
Simcere Pharmaceutical Group - Pipeline by Route of Administration, 2016 40
Simcere Pharmaceutical Group - Pipeline by Molecule Type, 2016 41
Simcere Pharmaceutical Group - Pipeline Products by Top 10 Mechanism of Action, 2016 42

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.